COLISTIMETHATE FOR INJECTION, USP 150 MG — DIN 02403544
COLISTIN (COLISTIMETHATE SODIUM) : 150 MG · FRESENIUS KABI CANADA LTD · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is COLISTIMETHATE FOR INJECTION, USP?
COLISTIMETHATE FOR INJECTION, USP 150 MG contains COLISTIN (COLISTIMETHATE SODIUM) : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02403544, held by FRESENIUS KABI CANADA LTD, supplied as POWDER FOR SOLUTION for INTRAVENOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 17-Dec-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is COLISTIMETHATE FOR INJECTION, USP used for?
Acute or chronic infections due to sensitive gram-negative bacilli, particularly P. aeruginosa, A. aerogenes, E. coli, and K. pneumoniae. Not for Proteus or Neisseria.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Colistin cost around the world?
Colistin is listed on 5 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Greece publishes a producer price (ex-factory); Hungary publishes a producer price (ex-factory); Iceland publishes a max wholesale. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Greece | producer price (ex-factory) | 16 | 16 | EUR███.██ |
| Hungary | producer price (ex-factory) | 2 | 2 | HUF███.██ |
| Iceland | max wholesale | 2 | 2 | ISK███.██ |
| Romania | max producer price | 1 | 1 | RON███.██ |
| Saudi Arabia | public | 1 | 1 | SAR███.██ |
22 pack listings across 22 brand entries and 4 price bases, refreshed 03 Sep 2026. Ranges span every Colistin pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Colistin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
4 holders have a Canadian DIN containing Colistin, across 4 DINs, of which 4 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| FRESENIUS KABI CANADA LTD | 1 | 1 | COLISTIMETHATE FOR INJECTION, USP | Sourceable in Canada |
| MARCAN PHARMACEUTICALS INC | 1 | 1 | COLISTIMETHATE FOR INJECTION USP | Sourceable in Canada |
| SEARCHLIGHT PHARMA INC | 1 | 1 | COLY-MYCIN M | Sourceable in Canada |
| STERIMAX INC | 1 | 1 | COLISTIMETHATE FOR INJECTION U.S.P. | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 150 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS ; INTRAMUSCULAR |
| Pack configuration (monograph) | Vials containing sodium colistimethate equivalent to 150 mg colistin base activity. |
| Storage | Powder: 15°C to 30°C. Reconstituted solution: 15°C to 30°C for up to 7 days. Infusion solutions: Use within 24 hours. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Colistin |
|---|---|
| ATC code | J01XB01 |
| AHFS class | 08:12.28.28 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02403544 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2403544 |
| Brand name | COLISTIMETHATE FOR INJECTION, USP |
| Generic / active ingredient | COLISTIN (COLISTIMETHATE SODIUM) : 150 MG |
| Market authorization holder | FRESENIUS KABI CANADA LTD |
| Health Canada schedule | Prescription |
| ATC code | J01XB01 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01XB |
| Current status | MARKETED |
| Status date | 17-Dec-2024 |
| Original market date | 2014-06-05 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Average dose: 2.5 mg/kg/day in 2-4 divided doses. Max 5 mg/kg/day for normal renal function. Administer IV (direct or infusion) or IM. Reduce dose in renal impairment.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Contraindicated in patients with a history of sensitivity to the drug.
Warnings and precautions
Maximum dose 5 mg/kg/day. May cause transient neurological disturbances (paresthesia, dizziness); do not drive. Overdose can cause renal insufficiency, muscle weakness, and apnea.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
4 of 4 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| COLISTIMETHATE FOR INJECTION U.S.P. | 150 MG | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | 02244849 |
| COLISTIMETHATE FOR INJECTION USP | 150 MG | POWDER FOR SOLUTION | MARCAN PHARMACEUTICALS INC | MARKETED | 02546639 |
| COLY-MYCIN M | 150 MG | POWDER FOR SOLUTION | SEARCHLIGHT PHARMA INC | MARKETED | 00476420 |
2 · Same class — other molecules in ATC J01XB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Colistin | COLISTIMETHATE FOR INJECTION U.S.P. · COLISTIMETHATE FOR INJECTION USP · COLISTIMETHATE FOR INJECTION, USP · COLY-MYCIN M | 4 | 4 | Yes |
| Polymyxin B | AEROSPORIN STERILE POWDER · POLYMYXIN B FOR INJECTION USP | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J01X
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J01XA | Dalbavancin · Telavancin · Vancomycin | 62 | 23 |
| J01XX | Bacitracin · Daptomycin · Fosfomycin · Lefamulin · Linezolid · +4 more | 52 | 15 |
| J01XE | Nitrofurantoin | 24 | 9 |
| J01XD | Metronidazole | 7 | 2 |
| J01XC | Fusidic Acid | 3 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is COLISTIMETHATE FOR INJECTION, USP called?
The same molecule, Colistin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| COLISTOP SUSP | Latin | Saudi Arabia |
| Colobreathe | Latin | Iceland |
| Colomycin | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.